1 July 2016

Borders & Southern declares delay

Ben Jaglom

Falklands-focused Borders & Southern (BOR) has reported that its Darwin East well will see delays of between four to five weeks.

The AIM 50 constituent announced that while operations are 'on-going' and the drilling has gone 'according to design' progress has been stalled due to what it describes as 'technical issues associated with rig equipment'. As a result it expects 'another 4 to 5 weeks of activity on the well' which lies off of the coast of the Falklands.

The news comes on the same day that Argentine foreign  minister Hector Timerman described the actions of UK oil exploration companies in the region as 'illegal' adding that the Argentinian government would seek legal action against those involved.

While AIM heavyweight Rockhopper (RKH) has so far been the only company to discover commercial quantities of oil, both Borders & Southern and Falkland Oil & Gas (FOGL) are still in the exploration phase.

It is difficult to ascertain to what extent the Argentinian government will seek to pursue claims against companies such as Rockhopper, and at the time of writing a military conflict looks a possibility, albeit an unlikely one.

Investors are advised to keep a close eye on developmentS between Argentina and AIM-quoted Falklands explorers, although it is worth noting the UK is expected to fully protect companies such as Rockhopper and Falkland Oil and Gas.

At 69.75p shares in Borders & Southern retain our speculative buy rating with the delay doing little to damage its long-term prospects.

Tags: AIM 50, Drilling in the Falklands, Potential conflict in the Falkla, Tensions in the Falklands

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

The robots are coming

Recent AIM newcomer Blue Prism (AIM: PRSM) has released a promising set of maiden results for the half year to April. Revenues grew by a handy 21 per cent and momentum seems to be accelerating with 33 new customers added to the 57 in place at the end of October. 

Avingtrans returns cash and remains a Buy

Having turned most of its market cap into cash through the sale of its aerospace division, it’s no surprise that Avingtrans (AIM: AVG) has been a very defensive stock during the recent turmoil. We now have some more details on the return of cash to shareholders which was promised as part of the disposal.

Omega investing in growth

Omega Diagnostics results looked positive and highlighted the progress being made in getting important new products to market. The investment to support those efforts will depress profits this year; but the market seems willing to look through this with Omega being a rare stock to be trading above its pre-Brexit level.

Stadium hit by profit warning

Stadium Group shares have been hit by a profit warning. This is a particular blow given the company’s progress in repositioning itself into a higher quality, design-led business.

Verona raises £42m to fund drug trials 

Verona Pharma (AIM: VRP) has raised an impressive £42 million net of costs which will fund phase II trials for its RPL554 compound. This drug targets severe respiratory diseases, in particular the 65 million worldwide sufferers from COPD (chronic obstructive pulmonary disease).

Income attractions at Belvoir

It’s fair to say that buy-to-let landlords have been under George Osborne’s cosh. He’s introduced a raised stamp duty rate and withdrawn higher-rate tax relief. However, Belvoir Lettings has seen little change in the market as far as its core lettings agency business is concerned. Furthermore, the shares have responded positively to a major acquisition which makes Belvoir the largest UK lettings agent.

More News